Fennec Pharmaceuticals Preliminary Report: Q4 Net Revenues Expected To Be $9.2M-$9.7M, Up 41%-49% Q/Q, FY23 Net Revenues Projected To Be $20.7M-$21.2M
Portfolio Pulse from Benzinga Newsdesk
Fennec Pharmaceuticals has released a preliminary report indicating a significant increase in Q4 net revenues, expected to be between $9.2M-$9.7M, marking a 41%-49% rise quarter over quarter. Furthermore, the company projects its FY23 net revenues to range between $20.7M-$21.2M.
February 29, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fennec Pharmaceuticals anticipates a significant quarterly revenue increase for Q4 and projects solid FY23 net revenues.
The substantial quarter-over-quarter revenue growth and positive FY23 revenue projections for Fennec Pharmaceuticals suggest a strong financial performance. This is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100